Natixis’s Tandem Diabetes Care TNDM Stock Holding History

Natixis’s Portfolio TNDM Stock Details TNDM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$105K	Buy	+5,500	New	+$120K	﹤0.01%	944
2025 Q3	–	Sell	-12,200	Closed	-$227K	–	1224
2025 Q2	$227K	Buy	+12,200	New	+$242K	﹤0.01%	784
2024 Q4	–	Sell	-12,200	Closed	-$517K	–	1188
2024 Q3	$517K	Buy	+12,200	New	+$517K	﹤0.01%	633
2023 Q2	–	Sell	-18,151	Closed	-$737K	–	1151
2023 Q1	$737K	Sell	18,151 -542	-3%	-$22.4K	0.01%	567
2022 Q4	$840K	Sell	18,693 -672	-3%	-$30.4K	﹤0.01%	660
2022 Q3	$968K	Sell	19,365 -854	-4%	-$46.8K	﹤0.01%	772
2022 Q2	$1.2M	Buy	+20,219	New	+$1.66M	﹤0.01%	783

Other funds holding TNDM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Sessa Capital New York $5.51B AUM 47.23% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

ACH

ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

GKIM

GW&K Investment Management Boston, Massachusetts $12.8B AUM 48.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Natixis's TNDM Position: Q1 2026 in Review

Natixis opened a new position in Tandem Diabetes Care (TNDM) in Q1 2026: 5,500 shares worth $105K. The stake represents ﹤0.01% of the portfolio and ranks #944 among its holdings. This is a return to the name: Natixis previously reported a position in TNDM as recently as Q2 2025.

Natixis first reported a position in TNDM in Q2 2022 and has held it in 7 quarters since. The position peaked at $1.2M in Q2 2022. 272 funds tracked by Wall St. Rank hold TNDM as of Q1 2026.

Natixis held 5,500 shares of Tandem Diabetes Care worth $105K as of Q1 2026.
Tandem Diabetes Care was a new Natixis position in Q1 2026.
Tandem Diabetes Care made up ﹤0.01% of Natixis's portfolio in Q1 2026, its #944 holding.
Natixis first reported a position in Tandem Diabetes Care in Q2 2022 and has held it in 7 quarters since.
Natixis's Tandem Diabetes Care position peaked at $1.2M in Q2 2022.
272 funds tracked by Wall St. Rank held Tandem Diabetes Care as of Q1 2026.

Based on Natixis's 13F filing for Q1 2026, filed 14 May 2026.